Table 5.
Eligibility for long-term treatment at week 24 postpartum (n = 568).
| Characteristics | Ineligible for Prophylactic TDF (n = 362 *) |
Eligible for Prophylactic TDF (n = 202 **) |
|||
|---|---|---|---|---|---|
| AASLD | LSM = F4 | 5 | 23% | 5 | 11% |
| HBeAg-pos & DNA ≥ 4.3 | 0 | 0% | 31 | 70% | |
| HBeAg-pos & DNA ≥ 4.3 & N < ALT ≤ 2N & LSM = F2 | 0 | 0% | 1 | 2% | |
| HBeAg-neg & DNA ≥ 3.3 & ALT > 2N | 13 | 59% | 7 | 16% | |
| HBeAg-neg & DNA ≥ 3.3 & N < ALT ≤ 2N & LSM = F2 | 4 | 18% | 0 | 0% | |
| TOTAL | 22 | 6% | 44 | 22% | |
| EASL | LSM = F4 | 5 | 24% | 4 | 9% |
| HBV DNA > 4.3 & ALAT > 2N | 2 | 10% | 13 | 30% | |
| HBV DNA > 3.3 & LSM = F2 | 14 | 67% | 12 | 28% | |
| HBeAg-pos & HBV DNA > 4.3 & age > 30 years old | 0 | 0% | 14 | 33% | |
| TOTAL | 21 | 6% | 43 | 21% | |
* AASLD: ALT ULN = 25 IU/L, F2 = 7 kPa, F4 = 11 kPa; ** ALT ULN = 40 IU/L, F2 = 6 kPa, F4 = 12 kPa if ALT = ] ULN − 5 × ULN [ or 9 kPa if ALT ≤ ULN.